NVCT
NASDAQ HealthcareNuvectis Pharma, Inc. - Common Stock
Biotechnology
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
๐ Market Data
| Price | $19.08 |
|---|---|
| Volume | 100,676 |
| Market Cap | 621.66M |
| Beta | -0.260 |
| RSI (14-Day) | 47.4 |
| 200-Day MA | $10.70 |
| 50-Day MA | $18.05 |
| 52-Week High | $29.27 |
| 52-Week Low | $5.55 |
| Forward P/E | -19.88 |
| Price / Book | 56.12 |
๐ฏ Investment Strategy Scores
NVCT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ฐ Dividend Daddy (50/100) โ this strategy High dividend yield + low volatility.
Lowest fit among scored strategies: ๐ Moon Shot (7/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NVCT in your text
Paste any article, transcript, or post โ the tool will extract NVCT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.